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We have characterized mature
breast milk, saliva, and plasma
IgA N-glycan profiles from lac-
tating individuals and studied the
potential differences among indi-
viduals who delivered infants
vaginally or by cesarean section.
The comparative analysis ob-
tained by nano-HPLC-chip/
TOF-MS reveals a body fluid-
specific profile of 50 N-glycan
species some of which can also
be influenced by delivery mode.
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Immunoglobulin A N-glycosylation Presents
Important Body Fluid-specific Variations in
Lactating Mothers*□S
Elisha Goonatilleke‡, Jennifer T. Smilowitz§¶, Karina V. Mariño, Bruce J. German§¶,
Carlito B. Lebrilla‡§**, and Mariana Barboza‡‡‡§§
Secretory Immunoglobulin A (SIgA) is central to mucosal
immunity: represents one of the main immunological mech-
anisms of defense against the potential attack of patho-
gens. During lactation SIgA is produced by plasmablasts in
the mammary gland and is present in breast milk, playing a
vital role in the passive immunity of the newborn. Interest-
ingly, the different components of SIgA are highly N-glyco-
sylated, and these N-Glycans have an essential role in
health maintenance. In this work, we performed a glycomic
study to compare N-glycosylation of SIgA purified from
mature breast milk and saliva, and plasma IgA from the
same lactating participants. Our results revealed a greater
diversity than previously reported, with 89 glycan composi-
tions that may correspond to over 250 structures. Among
these glycans, 54 glycan compositions were characterized
as body-fluid specific. Most of these unique N-Glycan com-
positions identified in SIgA from mature milk and IgA from
plasma were fucosylated and both fucosylated and sialy-
lated species, whereas in salivary SIgA the unique struc-
tures were mainly undecorated complex N-Glycans. In ad-
dition, we evaluated the effect of delivery mode on (S)IgA
glycosylation. Lactating participants who had given birth by
vaginal delivery presented an increased proportion of high
mannose and fucosylated glycans in salivary SIgA, and se-
lected high mannose, fucosylated, sialylated, and both fu-
cosylated and sialylated glycans in plasma IgA, indicating
that the hormonal changes during vaginal delivery could
affect plasma and saliva IgA. These results reveal the struc-
tural details that provide a new dimension to the roles of
(S)IgA N-Glycans in different tissues, and especially in ma-
ternal and new-born protection and infant development.
The design of optimal recombinant IgA molecules specifi-
cally targeted to protect mucosal surfaces will need to
include this dimension of structural detail. Molecular &
Cellular Proteomics 18: 2165–2177, 2019. DOI: 10.1074/mcp.
RA119.001648.
Immunoglobulin A (IgA)1 is a major component of the adapt-
ive immune system, being the most abundant immunoglobu-
lin expressed at mucosal surfaces and the second most abun-
dant immunoglobulin in circulation (1). Further, the human
body expends a substantial amount of energy to synthesize
serum and mucosal IgA daily, when compared with all the
other immunoglobulins combined (66 mg per 1kg of body
weight) (1, 2). In contrast to other immunoglobulins, IgA is
characterized by a unique structural heterogeneity. Secretory
IgA (SIgA) is present in mucosal secretions, including milk,
saliva, tears, intestinal, and cervical fluids. SIgA and can be
structurally classified as a homodimer, joined by a polypep-
tide (J chain); both components are produced by plasma cells
in the lamina propria of mucosal surfaces. This dimeric IgA is
then translocated across epithelial cells, and during this proc-
ess, the secretory component (which derives from the poly-
meric immunoglobulin receptor, pIgR) completes SIgA com-
plex formation via disulfide bonding. Two IgA subclasses or
isotypes have been described in mucosal surfaces: whereas
IgA1 carries an extra thirteen amino acids in the hinge region
of the heavy chain molecule, IgA2 is genetically polymorphic
and exists as three allotypes, designated IgA2m(1), IgA2m(2),
and IgA2n (3). Plasma IgA is predominantly monomeric and is
produced by bone marrow plasma cells. Plasma IgA is com-
posed of 90% of IgA1 and 10% of IgA2 (4). In contrast to
plasma IgA, which is mostly IgA1 subtype, SIgA presents both
isotypes with up to 50% of IgA2 isotype (4).
N-Glycosylation is a common post-translational modifica-
tion influencing protein structure and biological function, and
therefore, implying major roles in human health that are only
now addressable in structural detail (5, 6). Structurally, N-
Glycans can be classified in high mannose, complex, or hy-
brid N-Glycans. In an intricate biosynthesis that does not
follow a template, high mannose structures are produced in
the endoplasmic reticulum, and then can be further processed
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to hybrid or complex glycans, which can be decorated with
fucose or sialic acid residues. IgA is a heavily glycosylated
oligomeric complex (4). Both IgA1 and IgA2 contain two N-
glycosylation sites in the Fc region of the heavy chain,
whereas all the other allotypes of IgA2 carry two additional
N-glycosylation sites; moreover, IgA2m(2) and IgA2n contain
one additional N-glycosylation site (4). Glycosylation of SIgA
is even more complicated, as this glycoprotein assembly
comprises one additional N-glycosylation site on the J chain
and seven N-glycosylation sites on the secretory component.
Interestingly, removal of N-Glycans from both SIgA and free
secretory component drastically decreases the interaction
with Gram-positive bacteria highlighting the critical role of IgA
glycosylation in bacterial recognition (7), and recently, glycan-
lipopolysaccharide interactions were shown to contribute to
IgA coating of Gram-negative bacteria independently of anti-
body-epitope recognition (8). Further, studies have also dem-
onstrated that specific terminal monosaccharides in human
milk SIgA N-Glycans including mannose, galactose, fucose,
N-Acetylglucosamine, and sialic acid are potential binding
sites for respiratory and gastrointestinal pathogens including
Streptococcus pneumoniae, Helicobacter pylori, and Type
1-fimbriated E. coli (9–11).
Despite this critical biological role of IgA glycosylation in
bacterial attachment, pathogen decoy and clearance, struc-
tural characterization of SIgA N-glycome has lagged because
of its complexity and heterogeneity. However, advances in
liquid chromatography and mass spectrometry provided es-
sential tools for glycomics analysis (12, 13). We reported the
most extensive site-specific glycosylation analysis of SIgA in
human colostrum (14). Ruhaak, Bondt and colleagues char-
acterized plasma IgA N-glycome during pregnancy (15, 16).
And more recently, glycopeptides derived from salivary SIgA
from men and nonlactating women were reported (17). How-
ever, no systematic comparison of IgA glycosylation in multi-
ple body-fluids of the same lactating individual has so far
been reported.
Changes in glycosylation during pregnancy have been de-
scribed in plasma IgA (15, 16), and a recent human milk
N-glycome study showed that delivery mode affects the mot-
her’s milk glycome (18). Given that SIgA from breast milk
plays a crucial direct role in the passive immunity of the
newborn infant during lactation, and at the time that also
protects the lactating mother from infections, as well as
plasma IgA and salivary SIgA. Thus, there is a fundamental
question of whether the IgA in various tissues has identical or
different glycosylation for individual lactating mothers. In this
study, we characterized the mature breast milk and salivary
SIgA N-glycan profile and compared them to the N-glycan
profile obtained from plasma IgA purified from the same lac-
tating participants. Moreover, plasma IgA N-glycosylation of
nonlactating participants was used as a reference to evaluate
the influence of lactation. Additionally, we evaluated whether
the N-glycome of SIgA and plasma IgA could be altered by
delivery mode.
EXPERIMENTAL PROCEDURES
Chemicals and Materials—Staphylococcal super-like protein 7
(SSL7)/Agarose was purchased from InvivoGen (San Diego, CA).
Sodium phosphate and glycine were purchased from EMD Millipore
(Billerica, MA). Dialysis tubs (3MWCO) were obtained from Spectrum
Lab (Rancho Dominguez, CA). Glycerol free peptide N-glycosidase F
(PNGase F), alpha-2,3-neuraminidase, and alpha-2,3/6/8-neuramini-
dase were obtained from New England Biolabs (Ipswich, MA). Aceto-
nitrile was purchased from Honeywell (Morristown, NJ) and formic acid
was purchased from Fisher Scientific (Hanover Park, IL). Porous graph-
itized carbon cartridges (PGC) were obtained from Grace Davison Dis-
covery Sciences (Deerfield, IL). MilliQ water was used throughout the
experiment. Plasma IgA was purchased from Sigma-Aldrich (St.Louis,
MO).
Breast Milk, Saliva, and Plasma Samples
Lactation Study Participants—Breast milk, saliva, and plasma sam-
ples were obtained from a random subset of eight healthy women
enrolled in the parent cohort observational study (July 2009 -Feb
2014, Foods for Health Institute Lactation Study) at the University of
California, Davis (19). These paired samples were collected on day 71
postpartum from women who delivered healthy full-term infants (37
weeks gestation) either by vaginal delivery or cesarean C-section. The
blood type of all lactating participants was O positive.
Additionally, eight fasting plasma samples were collected from
gender, aged and blood-type matched nonlactating healthy partici-
pants enrolled in a single-blind, randomized-control, dietary fat post-
prandial pilot study and used as controls for this discovery project.
The UC Davis Institutional Review Board approved all aspects of both
studies, and informed consent was obtained from all participants. The
Davis cohort study was registered on clinicaltrials.gov (ClinicalTrials.
gov Identifier: NCT01817127).
Breast Milk Samples—Milk samples were collected by each par-
ticipant in the morning with a protocol based on the previously pub-
lished method (20), which involved removing milk from one breast
using a Harmony Manual Breast Pump (Medela Inc., McHenry, IL) 2–4
h after feeding her infant. Participants fully pumped one breast into a
bottle, inverted six times, transferred 12 ml into a 15 ml polypropylene
tube, and subsequently froze the sample in their kitchen freezers
(20 °C). Samples were picked up biweekly, transported to the lab on
dry ice, and stored at 80 °C until processing.
Saliva Samples—2 ml samples were collected into a polypropylene
tube by participants. Lactating participants avoided eating, drinking,
smoking, and use of oral hygiene products for a minimum of one hour
before saliva collection.
Plasma Samples—EDTA-whole blood was drawn after a 12-hour
fast. Samples were maintained on ice and centrifuged within 30 min
of the collection at 1,300  g at 4 °C for 10 min. After centrifugation,
plasma tubes were kept on ice during liquating and directly frozen at
80 °C until analyzed.
Immunoglobulin A Purification—SIgA from milk and saliva and IgA
from plasma were purified by affinity chromatography using SSL7/
agarose beads, as described earlier for milk samples and slightly
1 The abbreviations used are: IgA, Immunoglobulin A; SIgA, Secre-
tory Immunoglobulin A; pIgR, polymeric Immunoglobulin Receptor;
Hex, hexose; HexNAc, N-acetylhexosamine; GlcNAc, N-acetylgluco-
samine; Fuc, fucose; NeuAc, N-acetylneuraminic acid; PGC, porous
graphitized carbon; ECC, extracted compound chromatogram; EIC,
extracted ion chromatograms; SC, free IgA Secretory Component.
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modified for saliva and plasma samples (14). Briefly, milk and saliva
samples were centrifuged for 30 min at 13,000 rpm at 4 °C to remove
the cream and mucus layer, and the aqueous layer was transferred to
a new tube for further analysis. Empty columns were packed with 0.5
ml of SSL7/agarose beads and equilibrated with 10 mM sodium
phosphate in 150 mM sodium chloride buffer at pH 7.2 (buffer A).
Fractions obtained were loaded onto the column, and the flow-
through was reloaded three times. After washing with buffer A, IgA
was eluted with 0.1 M glycine (pH 2), and this solution was immedi-
ately neutralized by addition of 1 M phosphate buffer (pH 8). Samples
were dialyzed against 10 mM ammonium bicarbonate, concentrated,
and stored at 80 °C. Purity of SIgA and IgA samples was verified by
SDS-PAGE, followed by coomassie-blue staining and, protein con-
centration was determined by Bradford assay.
N-glycan Release and Enrichment—Aliquots of 50 g of purified
SIgA from milk and saliva and plasma IgA were reduced with dithio-
threitol (10 mM DTT in 50 mM NH4HCO3) and alkylated with iodoac-
etamide (20 mM IAA in 50 mM NH4HCO3, 30 min, RT, in the dark)
before deglycosylation. N-Glycans were enzymatically released with
PNGase F (2 l) (37 °C, 16hs) and purified by solid phase extraction
using graphitized carbon cartridges as previously described (21).
Briefly, cartridges were conditioned sequentially with 80% (v/v) ace-
tonitrile, 0.1% (v/v) trifluoroacetic (TFA) acid and water. Samples were
loaded onto the graphitized carbon cartridges (GCC) and washed
with water. Finally, N-Glycans were eluted with 40% (v/v) acetonitrile
in 0.05% (v/v) TFA. Samples were vacuum dried at room temperature
before mass spectrometry (MS) analysis. Similarly, commercial serum
IgA N-Glycans were also prepared and use as a standard for quality
control for the MS and tandem MS analysis.
Enzymatic Desialylation of N-Glycans—Purified N-Glycans from
milk, saliva, and plasma of lactating participants with vaginal delivery
and c-section were pooled separately. Glycans were then reduced
with 1 M NaBH4 in a 65 °C water bath for 1.5 h and desalted using
graphitized carbon cartridges as described in the previous section.
Digestions with alpha-2,3-neuraminidase or alpha-2,3/6/8-neuramin-
idase were performed in 0.1 M ammonium acetate pH 5.5 for 1.5 h at
37 °C. After digestion, samples were analyzed on a nano-HPLC-chip/
QTOF Mass Spectrometer. Control samples were incubated in the
same buffer without neuraminidases.
Nano-LC/MS and LC/MS/MS Analysis of N-Glycans—Purified N-
Glycans were reconstituted in 30 l of water and analyzed by nano-
HPLC-chip/TOF Mass Spectrometer (Agilent Technologies) using a
Porous Graphite Carbon (PGC) microfluidic chip as previously de-
scribed (22). Mass spectra were obtained at 1.5 s per spectrum with
a mass to charge (m/z) range of 400–2000 in positive ion mode.
Glycan masses were calibrated to an internal reference ion mass with
m/z 1221.991 value.
Tandem MS data for N-Glycans were obtained from N-glycan
samples from milk, saliva, and plasma of all participants using nano-
HPLC-chip/QTOF Mass Spectrometer (Agilent Technologies). The
chromatographic gradient and the column conditions used were iden-
tical to those used in the nano-HPLC-chip/TOF analysis. Tandem MS
was performed in the positive ion mode using the following parame-
ters optimized for N-glycan analysis: fragmentor 175V, skimmer 60V,
and octopole 1 RF 750V. Auto MS/MS mode was used with 0.63
spectra/second to obtain MS and MS/MS spectra. Glycans were
observed as singly and multiply charged ions ([MH], [M2H]2
and [M3H]3). Precursor ions were chosen based on the abun-
dance, and doubly charged ions were selected as priority, singly and
triply charged ions were given second and third place whereas all the
other charges were given least priority. Collision-induced dissociation
(CID) was applied with nitrogen gas depending on the m/z (mass/
charge) of the ions according to the following equation:
Vcollission  slope(m/z)  offset (Eq. 1)
where slope is (1.8/100 Da) V and offset is 2.4V.
The fragment ions of 772.3 m/z (Hex1HexNAc3) and 790 m/z
(Hex1HexNAc3H2O), 350.1 m/z (HexNAc1Fuc1), and 292.1 m/z
(NeuAc1) and 657.2 m/z (Hex1HexNAc1NeuAc1) were used to identify
bisecting GlcNAc, fucosylated, and sialylated species, respectively
(supplemental Fig. S1). Ion with m/z 790 corresponded to a C frag-
ment, whereas all other ions corresponded to nonreducing end or
internal B-type oxonium ions according to Domon & Costello nomen-
clature (23). Tandem MS spectra were annotated using in-house
software previously validated (24).
Data Analysis—N-Glycans were identified and quantified using Agi-
lent MassHunter Qualitative Analysis software (Version B. 06.01, Agi-
lent Technologies) in combination with an in-house retrosynthetic
N-glycan library of all possible glycan compositions according to
accurate mass (25) including complex, hybrid, and high mannose
glycan species. Glycan signals with ion counts below signal/noise
ratio of 5 were filtered out, and a 20 ppm mass error tolerance was
used to correlate the deconvoluted masses to the theoretical
masses. Tandem MS confirmation of library matches was previ-
ously validated, enabling rapid and accurate assignment of glycan
compounds (26, 27).
Relative abundance of individual glycan compositions was calcu-
lated by adding integrated peak area (ion counts) for all charge states
of a glycan mass and normalizing to the total peak area of all the
glycans present in the sample. The N-glycome for a) milk and saliva
SIgA, and b) plasma IgA was characterized in individual samples and
reported as average values for each glycan composition with relative
abundance  0.05% obtained from all individuals. All MS data and
annotated spectra have been stored at the MassIVE repository with
an identifier MSV000083029.
Statistical analyses were performed using JMP (SAS Institute Inc),
and the abundance of each glycan was log 10 transformed before
statistical analyses. One-way analysis of variance (ANOVA) was used
to compare glycans as the dependent variable among the three
sample types as the independent variable: breast milk, plasma, and
saliva. Tukey’s HSD test was used for multiple comparisons among
the sample types. Similarly, ANOVA and Tukey’s HSD analyses were
performed to compare glycan types from plasma IgA of lactating
(vaginal and C-section delivery mode) and nonlactating participants.
A two-tailed, t test was used to compare glycans between vaginal and
C-section delivery mode. All the statistical analyses had an alpha
value of 0.05
RESULTS
We analyzed the N-glycan profiles of SIgA isolated from
mature breast milk and saliva samples, and IgA isolated from
plasma as well. Nano-LC/MS analysis of IgA from all three body
fluids yielded nearly 90 unique glycan compositions, that may
correspond to over 250 structures combined (Fig. 1A). Glycans
were grouped into five different categories: high mannose, fu-
cosylated-only, sialylated-only, fucosylatedsialylated (simulta-
neously sialylated and fucosylated), and undecorated (neither
fucosylated nor sialylated), depending on their monosaccha-
ride composition and the presence or absence of fucose and
sialic acids as decorations. Additionally, glycans containing
bisecting GlcNAc and those that are terminally galactosylated
are reported separately but may contain several glycan struc-
tures of different categories. The relative abundances of bi-
secting GlcNAc structures were determined by summing the
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relative abundances of bisecting GlcNAc species. Similarly,
galactosylation was calculated by adding the relative abun-
dances of glycans with terminal galactoses. Mono-, di-, tri-,
and tetrafucosylation were calculated by summing the relative
abundances of glycans with one to four fucose residues,
respectively. Similarly, sialylation was determined depending
on the number of sialic acids present.
Mature Breast Milk SIgA N-Glycome Is Dominated by Fu-
cosylated and Simultaneously Fucosylated and Sialylated Gly-
cans—Over 70 glycan compositions were identified in SIgA
from mature breast milk, listed in the supplemental Table S1.
The isomers are provided along with their unique retention
times in supplemental Table S2A. Although the isomers are
readily identified, the exact structures (mainly linkages) have
not been elucidated. For milk, the two most abundant groups
were fucosylated-only (32%) and fucosylatedsialylated gly-
cans (28%) (Fig. 1B), whereas undecorated (17%) and sialy-
lated-only (14%) glycans were the next more abundant species.
High mannose glycans were the least abundant group (9%).
The most abundant species in milk SIgA N-glycome are
shown in the pie chart or glycan wheel in Fig. 2A and supple-
mental Table S3, with predominant biantennary structures. A
smaller fraction of triantennary and high mannose glycans
were also observed. Monofucosylation (42%) was a common
feature (Table I), whereas 12% of difucosylated glycans and
5% of trifucosylated glycans were also identified. Interest-
ingly, the majority of sialylated glycans were monosialylated
(36%). In mature breast milk SIgA, only 25% of the glycans
contained bisecting GlcNAc, and a high level of galactosyla-
tion was observed (55%).
FIG. 1. A, Representative N-glycosylation profiles of SIgA obtained from mature milk and saliva, and plasma IgA from the same
donor. High mannose glycans correspond to peaks in red. Complex and hybrid glycans without fucose or sialic acid were categorized as
undecorated glycans (orange peaks); glycans containing fucose were selected as fucosylated glycans (green peaks); glycans with sialic
acid were categorized as sialylated glycans (pink peaks); and glycans with both fucose and sialic acid were selected as fucosylated 
sialylated glycans (blue peaks). B, Relative abundances of N-glycan groups in mature breast milk and saliva SIgA, and plasma IgA.
Abundance for each glycan composition in all lactating participants was average to observed tissue-specific N-glycan variations.
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Fucosylated and Undecorated Glycans Are More Abundant
in Maternal Salivary SIgA N-Glycome—In salivary SIgA, simi-
larly over 70 different glycan compositions were identified
(supplemental Table S1) and corresponding isomers sepa-
rated (supplemental Table S2B). As in milk SIgA, salivary SIgA
also presented fucosylated-only glycans (37%) as the most
abundant group; however, undecorated glycans increased
(29%), whereas fucosylatedsialylated structures dropped to
13%, an abundance like that found for high mannose glycans
(12%). Interestingly, sialylated species were the least abun-
dant (9%).
As with mature milk, SIgA biantennary structures were
dominant in saliva, with a lower degree of triantennary, tet-
rantennary, and high mannose glycans (Fig. 2B and supple-
mental Table S4). Monofucosylated glycans (39%) were the
most abundant fucosylated species (Table I), with di- (5%)
and trifucosylated (5%) glycans in lower proportions. Al-
though sialylation was significantly lower than in mature milk
SIgA, most of the species were monosialylated (19%). In
comparison, glycans containing bisecting GlcNAc were sig-
nificantly higher (41%), and galactosylation (46%) was signif-
icantly lower than in mature breast milk SIgA.
Maternal Plasma IgA N-Glycome Is Dominated by Sialylated
and Simultaneously Fucosylated and Sialylated Glycans—In
contrast to the N-glycoprofiles described for mature breast
milk and salivary SIgA, the plasma IgA N-glycome presented
a somewhat lower diversity of glycan species, with over 50
different glycan compositions and isomers (supplemental Ta-
FIG. 2. N-glycan wheels of SIgA from (A) mature breast milk, (B) saliva, and IgA from (C) plasma are denoting individual relative
abundances of N-Glycans identified in each tissue. High mannose, undecorated, fucosylated, sialylated, and fucosylated  sialylated
glycans represented in shades of red, orange, green, pink and blue colors, respectively.
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ble S1 and supplemental Table S2C). Plasma IgA yielded a
high abundance of sialylated-only glycans (39%), followed by
fucosylatedsialylated glycans (32%). Undecorated (17%),
fucosylated-only (7%) and high mannose (6%) glycans were
the least abundant in plasma IgA.
As in SIgA from mature milk and saliva, the majority of the
abundant glycans in plasma IgA were biantennary, with a
lower degree of triantennary and high mannose glycans (Fig.
2C and supplemental Table S5). Monosialylation (45%) was a
common feature, and in contrast to what was found in SIgA,
disialylated glycans (23%) were also abundant (Table I). Al-
though fucosylation was significantly lower in plasma IgA
compared with SIgA from milk and saliva, almost all fucosy-
lated glycans were monofucosylated. Interestingly, in plasma
IgA, glycans containing bisecting GlcNAc (35%) were signifi-
cantly higher than mature milk SIgA, and galactosylation
(50%) was higher than salivary IgA.
Identification of IgA Body-fluid Specific N-glycan Profiles in
Breast Milk, Saliva, and Plasma—A comparative N-glycan
analysis of SIgA obtained from milk and saliva, and plasma
IgA allowed us to identify over 50 individual glycan composi-
tions that vary on their abundance in a body-fluid specific
manner. In mature milk SIgA, four N-Glycans were found to be
significantly more abundant than in salivary SIgA and plasma
IgA (Table II), and they corresponded to fucosylated-only, and
fucosylatedsialylated N-Glycans. Among them, monosialy-
lated biantennary glycans with one or two fucose residues
corresponded to the top two most abundant glycans in milk
SIgA. For salivary SIgA, twelve glycans were significantly
more abundant and corresponded to Man8, undecorated,
fucosylated-only, and fucosylatedsialylated glycans (Table
III). Although with low relative abundance, those glycans were
selectively present in salivary SIgA. Further, in plasma IgA, we
identified seventeen significantly abundant N-Glycans, and
they were among the undecorated, sialylated-only, and
fucosylatedsialylated glycan groups; eight of these were
also the most abundant glycans (Table IV).
Interestingly, we also found twenty-one glycans to be sig-
nificantly more abundant in SIgA from mature milk and saliva
than in circulating plasma IgA. The majority of these glycans
were fucosylated-only (71%), followed by fucosylated
sialylated (24%) and undecorated species (5%) (Table V).
Remarkably, five glycans corresponding to fucosylated-only
and fucosylatedsialylated were the most abundant species
observed in mature milk and saliva SIgA.
Delivery Mode Affects Mucosal and Systemic IgA N-glyco-
sylation—To evaluate whether the delivery mode affects
(S)IgA glycosylation, milk, and saliva SIgA and plasma IgA,
the N-glycosylation profiles from each body fluid obtained
from lactating participants who delivered their infants vag-
TABLE I













Galactosylation 55.40 (8.62) 45.86 (6.06) 49.73 (2.08) 0.0054 – –
Total Fucosylation 59.73 (10.05) 49.98 (6.09) 38.09 (4.40) 0.0229 0.0001 0.0009
Monofucosylation 41.88 (5.88) 38.77 (4.55) 37.37 (4.34) – – –
Difucosylation 11.57 (3.36) 5.15 (1.23) 0.49 (0.28) 0.0009 0.0001 0.0001
Trifucosylation 5.07 (1.94) 5.08 (1.89) 0.18 (0.12) – 0.0001 0.0001
Tetrafucosylation 1.14 (0.68) 0.98 (0.26) 0.05 (0.03) – 0.0001 0.0001
Total Sialylation 41.96 (16.25) 22.13 (10.70) 69.31 (4.20) 0.0013 0.0047 0.0001
Monosialylation 35.78 (12.14) 18.73 (7.41) 44.74 (2.88) 0.0004 – 0.0001
Disialylation 6.07 (4.30) 3.33 (3.44) 23.33 (2.46) 0.0498 0.0006 0.0001
Trisialylation 0.11 (0.04) 0.07 (0.04) 1.25 (0.63) – 0.0001 0.0001
Bisecting GlcNAc 25.26 (13.13) 41.04 (9.68) 35.34 (4.66) 0.0043 0.0205 –
aValues are reported as average relative abundance and standard deviation (S.D.), n  8.
bStatistically significant (p  0.05), highly significant (p  0.005).
TABLE II
Significantly more abundant N-Glycans in mature breast milk SIgA





Fucosylated-only Hex5HexNAc4Fuc1NeuAc0 3.13 1.31 0.30 0.0001 0.0001
Fucosylated  sialylated Hex5HexNAc4Fuc1NeuAc1 8.19 1.50 3.47 0.0001 0.0003
Hex5HexNAc4Fuc2NeuAc1 5.80 0.90 ND 0.0007 0.0001
Hex6HexNAc5Fuc2NeuAc1 0.51 0.10 0.07 0.0149 0.0002
Glycan composition is abbreviated as follows: Hex_HexNAc_Fuc_NeuAc where Hex  Hexose, HexNAc  N-Acetylhexosamine, Fuc 
Fucose, NeuAc  N-Acetylneuraminic Acid and subscript indicates the number of each monosaccharide residue. ND, not detected.
aValues are reported as average relative abundance, n  8.
bStatistically significant (p  0.05), highly significant (p  0.005).
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inally were compared with those from participants who de-
livered their infants by cesarean section (Fig. 3). In salivary
SIgA, lactating participants who delivered by c-section
showed lower levels of Man5 and bi- and triantennary fu-
cosylated glycans with one and up to four fucose resi-
dues (Hex5HexNAc4Fuc1NeuAc0, Hex4HexNAc3Fuc1NeuAc0,
Hex5HexNAc3Fuc1NeuAc0, and Hex6HexNAc5Fuc2–4NeuAc0);
and higher levels of bisecting agalacto-biantennary glycans
(Hex3HexNAc5Fuc0NeuAc0) (Fig. 3A). Notably, differences
were not restricted only to salivary SIgA, as plasma IgA from
lactating participants who delivered their infants by c-section
also showed lower levels in Man6, Man7, Man8, and Man 9.
Disialylated bi- and triantennary glycans (with compositions
Hex5HexNAc4Fuc0NeuAc2 and Hex5HexNAc5Fuc0NeuAc2)
were also significantly reduced in participants with c-section.
A similar trend was observed among the less abundant trisia-
lylated triantennary glycans (Hex6HexNAc5Fuc1NeuAc3) and
monosialylated hybrid glycans (Hex6HexNAc4Fuc0NeuAc1)
and monofucosylated glycans (Hex3HexNAc4Fuc1NeuAc0)
(Fig. 3B). No significant effects of delivery mode were ob-
served in milk SIgA N-Glycans.
Because sialylated glycans from plasma IgA seemed af-
fected by delivery mode, we also evaluated whether the dis-
tribution of sialic acid linkage type was also altered. By ana-
TABLE III
Significantly more abundant N-Glycans in salivary SIgA





High mannose Hex8HexNAc2 1.38 1.95 1.06 0.0181 0.0011
Undecorated Hex4HexNAc4Fuc0NeuAc0 1.47 2.45 0.93 0.0349 0.0139
Hex7HexNAc6Fuc0NeuAc0 0.38 2.23 ND 0.0032 0.0001
Hex3HexNAc4Fuc0NeuAc0 0.78 1.69 0.46 0.0191 0.0078
Hex5HexNAc3Fuc0NeuAc0 0.38 0.63 0.24 0.0202 0.0007
Fucosylated-only Hex4HexNAc4Fuc3NeuAc0 0.07 0.36 ND 0.0013 0.0007
Hex5HexNAc5Fuc4NeuAc0 ND 0.15 ND 0.0001 0.0001
Hex4HexNAc5Fuc2NeuAc0 ND 0.1 ND 0.0001 0.0044
Fucosylated  sialylated Hex5HexNAc4Fuc2NeuAc2 0.05 0.24 ND 0.0031 0.0006
Hex6HexNAc5Fuc4NeuAc2 ND 0.20 ND 0.003 0.0001
Hex5HexNAc4Fuc3NeuAc2 ND 0.15 ND 0.0011 0.0001
Hex6HexNAc5Fuc3NeuAc2 ND 0.12 ND 0.0001 0.0009
Glycan composition is abbreviated as follows: Hex_HexNAc_Fuc_NeuAc where Hex  Hexose, HexNAc  N-Acetylhexosamine, Fuc 
Fucose, NeuAc  N-Acetylneuraminic Acid and subscript indicates the number of each monosaccharide residue. ND, not detected.
aValues are reported as average relative abundance, n  8.
bStatistically significant (p  0.05), highly significant (p  0.005).
TABLE IV
Significantly more abundant N-Glycans in plasma IgA





Undecorated Hex5HexNAc5Fuc0NeuAc0 0.64 1.38 3.58 0.0001 0.0001
Hex5HexNAc4Fuc0NeuAc1 4.68 2.43 11.38 0.0001 0.0001
Hex5HexNAc5Fuc0NeuAc1 1.96 1.69 9.77 0.0001 0.0001
Hex4HexNAc5Fuc0NeuAc1 1.99 2.17 6.38 0.0001 0.0001
Hex5HexNAc4Fuc0NeuAc2 1.66 0.88 4.68 0.0058 0.0001
Sialylated-only Hex4HexNAc4Fuc0NeuAc1 0.79 0.72 1.51 0.0003 0.0001
Hex5HexNAc5Fuc0NeuAc2 0.22 0.14 1.37 0.0003 0.0001
Hex6HexNAc5Fuc0NeuAc3 ND ND 0.84 0.0001 0.0001
Hex6HexNAc5Fuc0NeuAc1 ND ND 0.24 0.0002 0.0001
Hex6HexNAc5Fuc0NeuAc2 ND ND 0.16 0.0001 0.0001
Hex5HexNAc5Fuc1NeuAc2 1.41 0.78 9.37 0.0005 0.0001
Hex5HexNAc5Fuc1NeuAc1 3.18 2.67 7.72 0.0018 0.0001
Hex5HexNAc4Fuc1NeuAc2 2.56 0.8 7.14 0.0016 0.0001
Fucosylated  sialylated Hex6HexNAc5Fuc1NeuAc2 0.11 ND 0.59 0.0027 0.0001
Hex6HexNAc5Fuc1NeuAc3 ND ND 0.31 0.0001 0.0001
Hex6HexNAc6Fuc1NeuAc1 ND ND 0.28 0.0001 0.0001
Hex6HexNAc6Fuc1NeuAc2 ND ND 0.15 0.0001 0.0001
Glycan composition is abbreviated as follows: Hex_HexNAc_Fuc_NeuAc where Hex  Hexose, HexNAc  N-Acetylhexosamine, Fuc 
Fucose, NeuAc  N-Acetylneuraminic Acid and subscript indicates the number of each monosaccharide residue. ND, not detected.
aValues are reported as average relative abundance, n  8.
bStatistically significant (p  0.05), highly significant (p  0.005).
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lyzing 16 different sialylated glycans after treatment with
specific alpha-2,3- and alpha-2,3/6/8-neuraminidase, we
found that the distribution of -2,3 and -2,6 linkage is not
significantly affected by delivery mode in plasma IgA (supple-
mental Fig. S2).
Finally, we compared the N-glycosylation profile of plasma
IgA from lactating participants with nonlactating female par-
ticipants. Notably, we found specific variations within high
mannose type glycans (Fig. 4), with significantly higher levels
of these structures in plasma IgA from lactating participants
who had a vaginal delivery, both when compared with non-
lactating participants (p  0.005) and lactating participants
who had delivered infants by c-section (p  0.05).
DISCUSSION
IgA is the most abundant immunoglobulin expressed at
mucosal surfaces and the second most abundant immuno-
globulin in circulation, playing a central role in both the innate
and adaptative immune systems. This study characterizes
and compares, for the first time, the N-glycosylation profiles
of mature breast milk and saliva secretory IgA (SIgA) and
plasma IgA obtained from the same lactating individuals us-
ing a highly-sensitive nano-HPLC-PGC-chip/TOF MS-based
method. The effect of delivery mode on IgA glycosylation was
also evaluated by comparing (S)IgA N-glycosylation profiles of
mothers that delivered babies vaginally or by c-section with
nonlactating women as controls.
The identification of over 70 glycan compositions is re-
ported in SIgA purified from mature breast milk and saliva,
respectively. A smaller number, 55 glycans compositions, was
obtained from plasma IgA. Interestingly, nearly 50% of all
these glycans compositions have not been described in milk,
saliva and plasma samples, which may be because of the
higher sensitivity of the approach using nano-HPLC-PGC-
chip/TOF mass spectrometry platform, thereby offering sig-
nificant advantages over alternative glycomic technologies
(28, 29).
The N-glycosylation profile for mature breast milk SIgA
obtained at 71 days postpartum showed higher levels of
fucosylation, galactosylation, and sialylation, and decreased
levels of bisecting GlcNAc (Table I) as compared with previ-
ously reported colostrum SIgA N-Glycans (1, 9). Over 30 new
glycans compositions are observed with mainly fucosylated
species (70%), carrying up to two fucose residues and with or
without sialic acids (supplemental Table S1). This increase in
N-glycan diversity in mature breast milk SIgA, and specifically
on fucosylated species, agrees with our previous work in
human milk lactoferrin glycosylation, where we have found an
increase in fucosylation during the transition from colostrum
to mature breast milk (30). This change in fucosylation could
TABLE V
Significantly more abundant N-Glycans in SIgA versus IgA





Undecorated Hex6HexNAc3Fuc0NeuAc0 0.32 0.40 0.11 0.0001 0.0001
Hex3HexNAc5Fuc1NeuAc0 7.83c,d 13.02e 1.56 0.0001 0.0001
Hex4HexNAc5Fuc1NeuAc0 6.22d 8.66e 2.25 0.0001 0.0001
Hex5HexNAc4Fuc2NeuAc0 4.06c 1.85e ND 0.0001 0.0001
Hex5HexNAc4Fuc3NeuAc0 3.43c 2.93e 0.06 0.0001 0.0001
Hex6HexNAc5Fuc4NeuAc0 0.79c 0.42 ND 0.0001 0.0001
Hex4HexNAc4Fuc1NeuAc0 0.69 1.02e 0.27 0.0001 0.0001
Hex6HexNAc5Fuc3NeuAc0 0.60c 0.21 ND 0.0001 0.0001
Fucosylated-only Hex4HexNAc3Fuc1NeuAc0 0.48c 0.65 0.05 0.0001 0.0001
Hex4HexNAc3Fuc2NeuAc0 0.29 0.49e ND 0.0001 0.0001
Hex5HexNAc3Fuc1NeuAc0 0.22c 0.49e ND 0.0001 0.0001
Hex5HexNAc3Fuc2NeuAc0 0.20 0.46e ND 0.0001 0.0001
Hex3HexNAc3Fuc1NeuAc0 0.19 0.39 0.05 0.0001 0.0001
Hex6HexNAc3Fuc1NeuAc0 0.15 0.22 ND 0.0001 0.0001
Hex4HexNAc4Fuc2NeuAc0 0.09 0.33e ND 0.0001 0.0001
Hex6HexNAc3Fuc2NeuAc0 0.05 0.38e ND 0.0001 0.0001
Fucosylated  sialylated Hex4HexNAc5Fuc1NeuAc1 3.65 2.86 0.90 0.0001 0.0001
Hex4HexNAc3Fuc1NeuAc1 0.79 0.55e 0.10 0.0001 0.0001
Hex5HexNAc4Fuc3NeuAc1 0.54 0.90e ND 0.0003 0.0001
Hex6HexNAc5Fuc3NeuAc1 0.39c 0.31 ND 0.0001 0.0001
Hex4HexNAc4Fuc1NeuAc1 0.34 0.28 0.09 0.0022 0.0034
Glycan composition is abbreviated as follows: Hex_HexNAc_Fuc_NeuAc where Hex  Hexose, HexNAc  N-Acetylhexosamine, Fuc 
Fucose, NeuAc  N-Acetylneuraminic Acid and subscript indicates the number of each monosaccharide residue. ND, not detected.
aValues are reported as average relative abundance, n  8.
bStatistically significant (p  0.05), highly significant (p  0.005).
cReported in the SC and the J chain by Royle et al, 2003 using N-glycan analysis.
dReported in the SC and the J chain by Huang et al, 2015 using glycopeptide analysis.
eReported in the SC and the J chain by Plomp et al, 2018 using glycopeptide analysis.
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be reflecting a common trend in the maturation of the human
milk N-glycome during lactation, and toward potentially pro-
tecting neonates from infectious diseases. The changes found
further suggest a specific enhanced pathogen decoy activity
in mature breast SigA to sequester bacteria and viruses,
preventing subsequent infection on the growing breastfeed-
ing infant. This notion is further supported by the increased
production of functionally relevant fucosylated and sialylated
structures on mature breast milk SIgA including Lewis and
sialyl-Lewis epitopes which have been shown to serve as
targets for bacterial lectins and adhesins (1) such as entero-
pathogenic Escherichia coli (31), Campylobacter jejuni (32),
Helicobacter pylori (11) and Noroviruses (33). Further, this
altered glycosylation can, in turn, influence the composition of
FIG. 3. Effect of delivery mode on
N-glycosylation of (A) salivary SIgA
and (B) plasma IgA. Relative abun-
dance of each IgA N-glycan was com-
pared between cesarean delivery and
vaginal delivery. Asterisks indicate the
statistical significance in the two groups,
p  0.05. Numbers represent glycan
compositions and each given value rep-
resents the number of each monosac-
charide residue in the following order
Hex-HexNAc-Fuc-NeuAc.
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the gut microbial community. Pioneering studies showed that
N-Glycans present on the SC of colostrum SIgA mediates
interactions with beneficial intestinal Gram-positive bacteria
(7, 8, 34). Recently, it was shown that human commensal
Gram-negative bacteria remodel their surface capsular poly-
saccharides to bind to SIgA N-Glycans, thereby enhancing
adhesion to intestinal epithelial cells and enabling stable mu-
cosal colonization. The bacteria produce mucus-associated
functional factors that facilitate symbiosis with members of
the Firmicutes phylum, protecting against colitis (8, 34, 35). In
this context, the role of individual milk SIgA N-Glycans in
shaping the composition of the beneficial gut microbiome
and maintaining intestinal homeostasis remains mainly un-
explored. The identification of mature breast milk SIgA N-
Glycans presented in this work provides a valuable frame-
work for future studies exploring the specific SIgA glycan
types that drive host-microbe symbiosis and intestinal ne-
onate well-being.
In this investigation, we also report the most comprehen-
sive N-glycoprofile of whole salivary SIgA and the first such
study using samples from lactating women, revealing a highly
diverse array of over 70 glycan compositions. To our knowl-
edge, only one recent publication in literature describes the
site-specific occupancy of salivary SIgA N-Glycans from men
and nonlactating women samples (17). Compared with Plomp
and colleagues, we observed higher levels of fucosylation,
galactosylation, sialylation, and bisecting GlcNAc, which is
likely because of sex differences as previously identified in
plasma IgA N-glycoprofiles (36). Likewise, methodological as-
pects may also account for these differences in key glycosy-
lation features, as we reported the relative abundance of each
modification in the complete N-glycome derived from whole
salivary SIgA, and Plomp reported each modification as the
number of fucose, galactose, and sialic acid residues per
glycan identified in a site-specific manner (17). Besides, we
have described a higher number of glycans species possibly
because of a difference in sample preparation, the higher
sensitivity of our LC-MS method of analysis, and type of
samples analyzed.
In this study, the comparison of the two mucosal SIgA
N-glycoprofiles (from mature breast milk and saliva samples)
obtained from the same participants unveiled significant qual-
itative similarities and quantitative differences. Interestingly,
the 30 most abundant glycans compositions were common to
both samples (Fig. 2A and 2B), but their abundances signifi-
cantly varied in a fluid-specific manner, suggesting that sim-
ilarities between milk and salivary SIgA could arise from their
mucosal origin, and as a result of certain biophysical require-
ments for SIgA stability and functionality. It has been shown
that selective removal of IgA heavy chain N-glycans alters the
proper protein conformation, resulting in degradation and re-
duced secretion, with marked reduced IgA dimer assembly
(37, 38). Remarkably, differences in crucial glycosylation fea-
tures were also observed: salivary SIgA displayed significantly
lower levels of sialylation, galactosylation, and fucosylation,
but higher levels of bisecting glycans than mature breast milk
SIgA (Table I). This decreased levels of sialylated glycans,
including sialylated-only and sialylatedfucosylated species,
in conjunction with higher levels of undecorated glycans ob-
served in salivary SIgA glycans, may result from the interac-
tion with glycosidases from oral cavity microbes such as
Fusobacterium, Neisseria, Porphyromonas and Tannerella,
which have been described as sialic acid scavengers (39–41).
Similarly, fucosylated glycans are the targets of the oral
yeast Candida albicans (42). Notably, we also identified body-
fluid specific glycans for milk and saliva samples, being sali-
va-specific glycans more diverse than in milk (Table II and III).
We could infer that differences between salivary and mature
milk SIgA N-glycans arise not only from a tissue-specific
mucosal N-glycosylation machinery but also result from an
evolutionary pressure toward the production of specific gly-
cans that will protect the mother from oral mucosal pathogens
and the newborn from gastrointestinal pathogens, respec-
tively. Potential functional differences of individual glycans
still need to be determined in SIgA from both mature breast
milk and saliva, and thus, further research is warranted.
This study characterized the most comprehensive plasma
IgA N-glycome reported thus far. N-Glycosylation analysis of
plasma IgA has received considerably more attention than
other body fluids given its potential biomarker role for a wide
range of human pathologies, including autoimmune diseases
and cancer. Altered IgA O-glycosylation including a decrease
in sialylation levels has been identified as a potential bio-
marker for IgA nephropathy (43, 44), and aberrant IgA N-gly-
cosylation has been reported in aging (36) and ovarian cancer
studies (45, 46). However, fewer studies have been con-
ducted on plasma IgA N-glycosylation in normal physiological
states such as pregnancy and lactation (15, 16). In agreement
with these reports, the most abundant glycoforms in plasma
IgA from lactating woman corresponded to fully processed
FIG. 4. Comparison of high mannose glycans observed in
plasma IgA of lactating participants according to the delivery
mode and nonlactating participants. p  0.05 is considered as
statistically significant.
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mono- and disialylated biantennary glycans with and without
bisecting GlcNAc and core fucosylation. However, among the
several additional species identified, agalacto- and mono-
galactosylated biantennary glycans with and without bisect-
ing GlcNAc, and mono- to trisialylated triantennary glycans
were among the most abundant. Interestingly, we confirmed
the presence of core-fucosylated triantennary glycans previ-
ously shown to be increased during pregnancy and up to 6
weeks post-delivery in SIgA1 heavy chain (Asn-340) (16).
Comparison of plasma IgA glycans with corresponding
SIgA glycans from mature breast milk and saliva yielded the
further characterization of 17 plasma-specific glycan compo-
sitions and additional 21 mucosal-specific glycan composi-
tions (Table IV and V). Remarkably, sialylated biantennary
glycans in plasma IgA were significantly more abundant that
in mature breast milk and saliva, and trisialylated triantennary
glycans were only observed in plasma IgA. A similar trend was
observed among the sialylated fucosylated glycans. This
higher content of sialylated species in plasma IgA may not
only reflect the tissue-specific glycosylation machinery of
bone marrow IgA-producing B-cells, but also the concerted
action of multiple mechanisms aimed at maintaining highly
sialylated circulating antibodies. First, sialic acid plays a key
role in determining the half-life of circulating proteins, so it is
possible that in the nursing mom IgA should be produced and
maintained in a highly sialylated state. Additionally, nonsialy-
lated IgA glycoforms are likely removed from circulation by
the asialoglycoprotein receptor in the liver (1), increasing the
relative abundance of sialylated glycoforms. Considering the
recent report of B-cells independent sialylation of IgG, a post-
secretion process regulated by the liver and platelets through
the corresponding release of sialyl-transferase ST6GalI and
sugar donor into the cardiovascular circulation (47), a similar
pathway for plasma IgA should not be discarded.
Notably, among the mucosal specific glycans identified in
SIgA, sixteen of them were mapped in the secretory compo-
nent and J chain (14, 17). This finding indicates that glycosy-
lation differences between circulating IgA and mucosal di-
meric SIgA, and precisely the reduced diversity of glycans in
plasma IgA, may also arise from the almost complete pre-
dominance of monomeric IgA and the absence of secretory
component and J chain in plasma IgA. This likely also reflects
an evolutionary adaptation to the mainly aseptic circulating
environment in contrast to the oral mucosal cavity and gas-
trointestinal tract environments that harbor complex microbial
communities of symbionts and pathobiont bacteria, fungi, and
viruses.
We also observed that delivery mode affected N-glycans on
plasma IgA and salivary SIgA in a body-fluid specific manner,
evidencing a potential role of hormonal regulation of IgA gly-
cosylation. The hormonal balance between estrogens and
progesterone is critical for the maintenance of pregnancy, the
onset of labor, and lactation. In humans, vaginal delivery
results from a complex and dynamic sequence of endocrine
events that involves a decreased production of progesterone,
increase production of estrogens and prostaglandins and in-
crease levels of oxytocin and relaxin (48). Such a cascade of
events and shift in maternal circulating hormone levels at the
end of pregnancy may not equally take place during delivery
by c-section. Therefore, it is possible that circulating estrogen
levels may be altered in women who delivered a baby by
c-section. Interestingly, estrogens have been shown to regu-
late sialylation and corresponding functional properties of
circulating gonadotrophins (LH, FSH, and CG) (49). Thus, our
results of lower level of sialylated glycans in plasma IgA in
women that delivered by c-section may result from a poten-
tially lower level of estrogen at least at the time of delivery.
Further research is needed to elucidate the impact and bio-
logical significance of differences in IgA glycosylation and
maternal health.
In conclusion, this study has characterized and compared
for the first time the secretory IgA N-glycoprofile of mature
breast milk and saliva with plasma IgA of the same lactating
individuals who delivered their infants vaginally or by c-sec-
tion. The comparative analysis obtained by nano-HPLC-chip/
TOF-MS revealed a greater diversity of glycans than reported
thus far and over 50 body-fluid specific N-glycan compositions,
some of which are also influenced by delivery mode. This study
could be necessary to better understand the maternal control of
(S)IgA glycosylation and for unraveling the functional role of
mature milk SIgA N-Glycans that drives the assembly of the gut
microbiota and promotes neonate well-being. Similarly, the de-
sign of optimal recombinant IgA molecules specifically targeted
to protect mucosal surfaces will need to include this dimen-
sion of structural detail. We expect that the current study
may also guide salivary SIgA-glycan based-biomarker re-
search efforts for the diagnostic of oral cavity diseases such
as periodontitis, Sjogren’s syndrome, and systemic condi-
tions such as pulmonary and kidney diseases, B-cells pa-
thologies (e.g. rheumatoid arthritis, systemic lupus erythe-
matosus, multiple sclerosis), cancer or infectious diseases.
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